Phase II trial of bevacizumab (A), lenalidomide (R), docetaxel (D), and prednisone (P) in patients (pts)with metastatic castration-resistant prostate cancer (mCRPC) Journal Articles uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Huang, X
  • Ning, YM
  • Gulley, JL
  • Kluetz, PG
  • Adelberg, D
  • Mulquin, M
  • Madan, RA
  • Bassim, Carol Walker
  • Figg, WD
  • Dahut, WL

publication date

  • March 1, 2011